Bailard, Inc. Biomarin Pharmaceutical Inc Transaction History

Bailard, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 27, 2022	SELL	$71.48 - $86.85 $209,364 - $254,383	-2,929 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$74.28 - $92.69 $43,528 - $54,316	-586 Reduced 16.67%	2,929 $226,000
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $252,095 - $321,517	3,515 New	3,515 $311,000
Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $299,080 - $341,880	-4,000 Closed	0 $0
Q1 2019 Apr 24, 2019	SELL	$84.2 - $98.62 $84,200 - $98,620	-1,000 Reduced 20.0%	4,000 $355,000
Q2 2018 Aug 08, 2018	BUY	$76.01 - $99.03 $76,010 - $99,030	1,000 Added 25.0%	5,000 $471,000
Q1 2018 May 07, 2018	SELL	$77.67 - $92.63 $7,767 - $9,263	-100 Reduced 2.44%	4,000 $324,000
Q4 2017 Feb 08, 2018	BUY	$80.76 - $95.13 $169,596 - $199,773	2,100 Added 105.0%	4,100 $0
Q4 2015 Jan 29, 2018	BUY	N/A	2,000	2,000 $0

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.